A new study from Oregon State University has shaken the psychedelics community after researchers discovered that many so-called “magic mushroom” edibles contained no psilocybin at all. Instead, chemical analysis revealed the presence of synthetic compounds and mislabeled psychoactive substances, exposing major risks in the unregulated market for psychedelic products.
The study, published September 11, 2025, analyzed a broad selection of chocolate bars, gummies, and infused edibles marketed as containing psilocybin—the psychoactive compound found in magic mushrooms. To the researchers’ surprise, a majority of samples contained zero detectable psilocybin or psilocin. Instead, many products included synthetic hallucinogens or other chemicals not disclosed on the label.
This is the first large-scale study of its kind in the United States. Researchers said their results indicate widespread mislabeling, contamination, or intentional substitution within the gray-market industry, where products are sold in states that have not yet established clear regulatory frameworks for psilocybin.
“Consumers believe they’re buying natural psilocybin products, but in many cases, they’re ingesting unknown synthetics,” said Dr. Rachel Winters, lead researcher on the study. “This raises serious health and legal concerns.”
Oregon and Colorado are currently the only states to establish regulated pathways for psilocybin therapy, but across the U.S., unregulated markets have surged. Smoke shops, online vendors, and underground dealers openly sell mushroom-branded edibles. The Oregon State study suggests that many of these items bear little resemblance to actual psilocybin mushrooms.
This mislabeling comes at a time of rapidly growing consumer demand. The U.S. psychedelic industry is projected to reach $12 billion by 2030, with wellness consumers seeking natural alternatives to pharmaceuticals. But without oversight, experts warn of public health consequences similar to the vape crisis of 2019, when unregulated THC cartridges caused lung injuries nationwide.
For consumers, the risks include:
For the industry, the findings highlight a credibility crisis. Licensed producers in Oregon’s regulated psilocybin therapy system may gain an advantage, as consumers seek tested, reliable products. However, the gray market’s dominance raises questions about how regulators can close the gap between demand and legal supply.
“This study proves that without regulation, people cannot trust the label on their psychedelic products,” said cannabis and psychedelics attorney David Bronstein. “It’s a wake-up call for lawmakers.”
Despite these steps, most U.S. consumers access psilocybin through underground or quasi-legal markets, where quality control is absent. The Oregon State study underscores the risks of expanding consumer access without parallel safety standards.
Experts say the findings could accelerate calls for federal regulation or state-level safety testing, similar to cannabis markets. Industry advocates argue that consumer safety and market legitimacy depend on laboratory verification.
In the near term, consumers are advised to exercise caution when purchasing mushroom edibles, especially online. Advocates are urging policymakers to prioritize funding for public education and testing infrastructure.
